Immunoactive effects of cannabinoids: Considerations for the therapeutic use of cannabinoid receptor agonists and antagonists

International Immunopharmacology

Volumn 10, Issue 5, 2010, Pages 547-555

  Greineisen, William E ^a,b   Turner, Helen ^a,b  

^a CHAMINADE UNIVERSITY OF HONOLULU   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

Cannabinoids; GPCR; Immunosuppression; Metabolic disorders; Neuroimmunology; Signaling

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 [2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL]CYCLOHEXANOL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; AR 171416A; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; DOCOSATETRAENOYLETHANOLAMIDE; DRONABINOL; HOMO GAMMA LINOLENOYLETHANOLAMIDE; JWH 139; L 759633; L 759656; METHANANDAMIDE; NOLADIN ETHER; O 1812; O 1821; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; ANOREXIA; BRAIN DISEASE; CACHEXIA; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG MECHANISM; EATING DISORDER; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MEMORY DISORDER; METABOLIC SYNDROME X; NEOPLASM; NONHUMAN; OBESITY; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STROKE; SYNCOPE; TRANSIENT ISCHEMIC ATTACK; WASTING SYNDROME; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CANNABINOIDS; CYTOKINES; DRUG ADMINISTRATION ROUTES; HISTAMINE RELEASE; HUMANS; HYPERSENSITIVITY; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; INFLAMMATORY BOWEL DISEASES; PHAGOCYTOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 77950504056     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.02.012     Document Type: Review

References (129)

1. Mechoulam R. Looking back at Cannabis research. Curr Pharm Des 6 (2000) 1313-1322
2. Mechoulam R., and Hanus L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids 108 (2000) 1-13
3. Gaoni Y., and Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 93 (1971) 217-224
4. Marx J. Marijuana receptor gene cloned. Science 249 (1990) 624-626
5. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
6. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
7. Howlett A.C. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35 (1995) 607-634
8. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 (2002) 161-202
9. Pertwee R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 30 Suppl 1 (2006) S13-S18
10. Childers S.R., and Deadwyler S.A. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem Pharmacol 52 (1996) 819-827
11. Childers S.R., Pacheco M.A., Bennett B.A., Edwards T.A., Hampson R.E., Mu J., et al. Cannabinoid receptors: G-protein-mediated signal transduction mechanisms. Biochem Soc Symp 59 (1993) 27-50
12. Graham E.S., Ashton J.C., and Glass M. Cannabinoid receptors: a brief history and "what's hot". Front Biosci 14 (2009) 944-957
13. Mechoulam R., Fride E., and Di Marzo V. Endocannabinoids. Eur J Pharmacol 359 (1998) 1-18
14. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 58 (1999) 315-348
15. Hampson R.E., and Deadwyler S.A. Cannabinoids, hippocampal function and memory. Life Sci 65 (1999) 715-723
16. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., and Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 96 (1999) 5780-5785
17. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6 (1999) 635-664
18. Fadda P., Robinson L., Fratta W., Pertwee R.G., and Riedel G. Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology 47 (2004) 1170-1179
19. Kumar R.N., Chambers W.A., and Pertwee R.G. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 56 (2001) 1059-1068
20. Carr T.P., Jesch E.D., and Brown A.W. Endocannabinoids, metabolic regulation, and the role of diet. Nutr Res 28 (2008) 641-650
21. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., et al. The cannabinoid system and immune modulation. J Leukoc Biol 74 (2003) 486-496
22. Massa F., and Monory K. Endocannabinoids and the gastrointestinal tract. J Endocrinol Investig 29 (2006) 47-57
23. Sarzani R. Endocannabinoids, blood pressure and the human heart. J Neuroendocrinol 20 Suppl 1 (2008) 58-62
24. Storr M.A., and Sharkey K.A. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol 7 (2007) 575-582
25. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 108 (2000) 169-190
26. Cabral G.A., and Staab A. Effects on the immune system. Handb Exp Pharmacol (2005) 385-423
27. Hollister L.E. Marijuana and immunity. J Psychoactive Drugs 24 (1992) 159-164
28. Zurier R.B. Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem 88 (2003) 462-466
29. Pestonjamasp V.K., and Burstein S.H. Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim Biophys Acta 1394 (1998) 249-260
30. Bisogno T., Maurelli S., Melck D., De Petrocellis L., and Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 272 (1997) 3315-3323
31. Karsak M., Gaffal E., Date R., Wang-Eckhardt L., Rehnelt J., Petrosino S., et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316 (2007) 1494-1497
32. Massa F., Storr M., and Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 83 (2005) 944-954
33. Klein T.W., Newton C., Larsen K., Chou J., Perkins I., Lu L., et al. Cannabinoid receptors and T helper cells. J Neuroimmunol 147 (2004) 91-94
34. Klein T.W., Newton C.A., Nakachi N., and Friedman H. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol 164 (2000) 6461-6466
35. Newton C.A., Klein T.W., and Friedman H. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Immun 62 (1994) 4015-4020
36. Wang M., Richards A.L., Friedman H., and Djeu J.Y. Selective inhibition of natural killer but not natural cytotoxic activity in a cloned cell line by delta-9-tetrahydrocannabinol. J Leukoc Biol 50 (1991) 192-197
37. Nahas G.G., Suciu-Foca N., Armand J.P., and Morishima A. Inhibition of cellular mediated immunity in marihuana smokers. Science 183 (1974) 419-420
38. Petersen B.H., Lemberger L., Graham J., and Dalton B. Alterations in the cellular-mediated immune responsiveness of chronic marihuana smokers. Psychopharmacol Commun 1 (1975) 67-74
39. Trisler K., and Specter S. Delta-9-tetrahydrocannabinol treatment results in a suppression of interleukin-2-induced cellular activities in human and murine lymphocytes. Int J Immunopharmacol 16 (1994) 593-603
40. El-Gohary M., and Eid M.A. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum Exp Toxicol 23 (2004) 149-156
41. Carlisle S.J., Marciano-Cabral F., Staab A., Ludwick C., and Cabral G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2 (2002) 69-82
42. Correa F., Mestre L., Docagne F., and Guaza C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol 145 (2005) 441-448
43. Gokoh M., Kishimoto S., Oka S., Metani Y., and Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. FEBS Lett 579 (2005) 6473-6478
44. Maresz K., Carrier E.J., Ponomarev E.D., Hillard C.J., and Dittel B.N. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95 (2005) 437-445
45. Fischer-Stenger K., Updegrove A.W., and Cabral G.A. Delta 9-tetrahydrocannabinol decreases cytotoxic T lymphocyte activity to herpes simplex virus type 1-infected cells. Proc Soc Exp Biol Med 200 (1992) 422-430
46. Pross S., Nakano Y., Smith J., Widen R., Rodriguez A., Newton C., et al. Suppressive effect of tetrahydrocannabinol on specific T cell subpopulations in the thymus. Thymus 19 (1992) 97-104
47. Lu T., Newton C., Perkins I., Friedman H., and Klein T.W. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J Pharmacol Exp Ther 319 (2006) 269-276
48. Raborn E.S., Marciano-Cabral F., Buckley N.E., Martin B.R., and Cabral G.A. The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. J Neuroimmune Pharmacol 3 (2008) 117-129
49. Ueda Y., Miyagawa N., and Wakitani K. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Life Sci 80 (2007) 414-419
50. Buckley N.E. The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 153 (2008) 309-318
51. Yuan J., and Yankner B.A. Apoptosis in the nervous system. Nature 407 (2000) 802-809
52. Zhu W., Igarashi T., Qi Z.T., Newton C., Widen R.E., Friedman H., et al. Delta-9-Tetrahydrocannabinol (THC) decreases the number of high and intermediate affinity IL-2 receptors of the IL-2 dependent cell line NKB61A2. Int J Immunopharmacol 15 (1993) 401-408
53. Kaminski N.E. Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. J Neuroimmunol 83 (1998) 124-132
54. McCoy K.L., Gainey D., and Cabral G.A. Delta 9-Tetrahydrocannabinol modulates antigen processing by macrophages. J Pharmacol Exp Ther 273 (1995) 1216-1223
55. Giudice E.D., Rinaldi L., Passarotto M., Facchinetti F., D'Arrigo A., Guiotto A., et al. Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells. J Leukoc Biol 81 (2007) 1512-1522
56. Granberg M., Fowler C.J., and Jacobsson S.O. Effects of the cannabimimetic fatty acid derivatives 2-arachidonoylglycerol, anandamide, palmitoylethanolamide and methanandamide upon IgE-dependent antigen-induced beta-hexosaminidase, serotonin and TNF alpha release from rat RBL-2H3 basophilic leukaemic cells. Naunyn Schmiedebergs Arch Pharmacol 364 (2001) 66-73
57. Jonsson K.O., Persson E., and Fowler C.J. The cannabinoid CB2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of beta-hexosaminidase from skin slices in vitro. Life Sci 78 (2006) 598-606
58. Lau A.H., and Chow S.S. Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells. Eur J Pharmacol 464 (2003) 229-235
59. Samson M.T., Small-Howard A., Shimoda L.M., Koblan-Huberson M., Stokes A.J., and Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170 (2003) 4953-4962
60. Small-Howard A.L., Shimoda L.M., Adra C.N., and Turner H. Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. Biochem J 25 (2005) 25
61. Melvin L.S., Milne G.M., Johnson M.R., Subramaniam B., Wilken G.H., and Howlett A.C. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 44 (1993) 1008-1015
62. Pertwee R.G. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs 9 (2000) 1553-1571
63. Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 42 (2006) 495-503
64. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 105 (2006) 1-25
65. Tyson L.B., Gralla R.J., Clark R.A., Kris M.G., Bordin L.A., and Bosl G.J. Phase 1 trial of levonantradol in chemotherapy-induced emesis. Am J Clin Oncol 8 (1985) 528-532
66. Gifford A.N., Tang Y., Gatley S.J., Volkow N.D., Lan R., and Makriyannis A. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci Lett 238 (1997) 84-86
67. Lindsey K.P., Glaser S.T., and Gatley S.J. Imaging of the brain cannabinoid system. Handb Exp Pharmacol (2005) 425-443
68. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350 (1994) 240-244
69. Zanella M.T., and Ribeiro Filho F.F. Emerging drugs for obesity therapy. Arq Bras Endocrinol Metabol 53 (2009) 271-280
70. McPartland J.M. Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship. PLoS ONE 4 (2009) e5092
71. Moreira F.A., and Crippa J.A. The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 31 (2009) 145-153
72. Moreira F.A., Grieb M., and Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 23 (2009) 133-144
73. Rhee M.H., and Kim S.K. SR144528 as inverse agonist of CB2 cannabinoid receptor. J Vet Sci 3 (2002) 179-184
74. Shire D., Calandra B., Bouaboula M., Barth F., Rinaldi-Carmona M., Casellas P., et al. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci 65 (1999) 627-635
75. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284 (1998) 644-650
76. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404 (2000) 84-87
77. Mechoulam R., Fride E., Hanus L., Sheskin T., Bisogno T., Di Marzo V., et al. Anandamide may mediate sleep induction. Nature 389 (1997) 25-26
78. Terranova J.P., Storme J.J., Lafon N., Perio A., Rinaldi-Carmona M., Le Fur G., et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berlin) 126 (1996) 165-172
79. Campillo N.E., and Paez J.A. Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease. Mini Rev Med Chem 9 (2009) 539-559
80. Krishnan S., Cairns R., and Howard R. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev (2009) CD007204
81. Orgado J.M., Fernandez-Ruiz J., and Romero J. The endocannabinoid system in neuropathological states. Int Rev Psychiatry 21 (2009) 172-180
82. Iuvone T., Esposito G., De Filippis D., Scuderi C., and Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders?. CNS Neurosci Ther 15 (2009) 65-75
83. Sewell R.A., Ranganathan M., and D'Souza D.C. Cannabinoids and psychosis. Int Rev Psychiatry 21 (2009) 152-162
84. Tucker P. Substance misuse and early psychosis. Australas Psychiatry 17 (2009) 291-294
85. Rathbone J., Variend H., and Mehta H. Cannabis and schizophrenia. Cochrane Database Syst Rev (2008) CD004837
86. Zammit S., Spurlock G., Williams H., Norton N., Williams N., O'Donovan M.C., et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry 191 (2007) 402-407
87. Tsai S.J., Wang Y.C., and Hong C.J. Association study between cannabinoid receptor gene (CNR1) and pathogenesis and psychotic symptoms of mood disorders. Am J Med Genet 105 (2001) 219-221
88. Deadwyler S.A., Hampson R.E., Mu J., Whyte A., and Childers S. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther 273 (1995) 734-743
89. Deadwyler S.A., Hampson R.E., Bennett B.A., Edwards T.A., Mu J., Pacheco M.A., et al. Cannabinoids modulate potassium current in cultured hippocampal neurons. Receptors Channels 1 (1993) 121-134
90. Jordt S.E., Bautista D.M., Chuang H.H., McKemy D.D., Zygmunt P.M., Hogestatt E.D., et al. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427 (2004) 260-265 Electronic publication 2004 Jan 7
91. Ross R.A. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 140 (2003) 790-801 Electronic publication 2003 Sep 29
92. van der Stelt M., Trevisani M., Vellani V., De Petrocellis L., Schiano Moriello A., Campi B., et al. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. Embo J 24 (2005) 3026-3037
93. Cabral G.A., and Dove Pettit D.A. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 83 (1998) 116-123
94. De Filippis D., D'Amico A., and Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol 20 Suppl 1 (2008) 20-25
95. Beal J.E., Olson R., Laubenstein L., Morales J.O., Bellman P., Yangco B., et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10 (1995) 89-97
96. Kirkham T.C. Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 16 (2005) 297-313
97. Samat A., Tomlinson B., Taheri S., and Thomas G.N. Rimonabant for the treatment of obesity. Recent Pat Cardiovasc Drug Discov 3 (2008) 187-193
98. Gaetani S., Kaye W.H., Cuomo V., and Piomelli D. Role of endocannabinoids and their analogues in obesity and eating disorders. Eat Weight Disord 13 (2008) e42-e48
99. Myrianthefs P.M., and Batistaki C. Cancer cachexia and immunomodulation. J BUON 10 (2005) 181-188
100. Robertson R.G., and Montagnini M. Geriatric failure to thrive. Am Fam Physician 70 (2004) 343-350
101. Ghodse A.H. Cannabis psychosis. Br J Addict 81 (1986) 473-478
102. Hall W., and Degenhardt L. Cannabis use and the risk of developing a psychotic disorder. World Psychiatry 7 (2008) 68-71
103. D'Souza D.C., Ranganathan M., Braley G., Gueorguieva R., Zimolo Z., Cooper T., et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33 (2008) 2505-2516
104. Shukla P.C., and Moore U.B. Marijuana-induced transient global amnesia. South Med J 97 (2004) 782-784
105. Mayoral M., Calderon H., Cano R., and Lombardero M. Allergic rhinoconjunctivitis caused by Cannabis sativa pollen. J Investig Allergol Clin Immunol 18 (2008) 73-74
106. Williams C., Thompstone J., and Wilkinson M. Work-related contact urticaria to Cannabis sativa. Contact Dermat 58 (2008) 62-63
107. Degenhardt L., and Hall W.D. The adverse effects of cannabinoids: implications for use of medical marijuana. Cmaj 178 (2008) 1685-1686
108. Hill S., and Thomas S.H. Recreational drug toxicity. Clin Med 8 (2008) 99-103
109. Rubino T., and Parolaro D. Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol 286 (2008) S108-S113
110. Tashkin D.P. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis 63 (2005) 93-100
111. Abrams D.I., Hilton J.F., Leiser R.J., Shade S.B., Elbeik T.A., Aweeka F.T., et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 139 (2003) 258-266
112. Bredt B.M., Higuera-Alhino D., Shade S.B., Hebert S.J., McCune J.M., and Abrams D.I. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol 42 (2002) 82S-89S
113. Kaslow R.A., Blackwelder W.C., Ostrow D.G., Yerg D., Palenicek J., Coulson A.H., et al. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. A report from the Multicenter AIDS Cohort Study. JAMA 261 (1989) 3424-3429
114. Pacifici R., Zuccaro P., Farre M., Poudevida S., Abanades S., Pichini S., et al. Combined immunomodulating properties of 3, 4-methylenedioxymethamphetamine (MDMA) and cannabis in humans. Addiction 102 (2007) 931-936
115. Pacifici R., Zuccaro P., Pichini S., Roset P.N., Poudevida S., Farre M., et al. Modulation of the immune system in cannabis users. JAMA 289 (2003) 1929-1931
116. Maykut M.O. Health consequences of acute and chronic marihuana use. Prog Neuropsychopharmacol Biol Psychiatry 9 (1985) 209-238
117. Klein T.W., Newton C., and Friedman H. Cannabinoid receptors and immunity. Immunol Today 19 (1998) 373-381
118. Buckland M.S., and Pinching A.J. Immunology of HIV-filling in the details. Int J STD AIDS 15 (2004) 574-582 quiz 83
119. Miedema F. Immunological abnormalities in the natural history of HIV infection: mechanisms and clinical relevance. Immunodefic Rev 3 (1992) 173-193
120. Pinching A.J. HIV/AIDS pathogenesis and treatment: new twists and turns. Curr Opin Immunol 3 (1991) 537-542
121. Esper D.H., and Harb W.A. The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr Clin Pract 20 (2005) 369-376
122. Ramos E.J., Suzuki S., Marks D., Inui A., Asakawa A., and Meguid M.M. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 7 (2004) 427-434
123. Das U.N. Is obesity an inflammatory condition?. Nutrition 17 (2001) 953-966
124. Maachi M., Pieroni L., Bruckert E., Jardel C., Fellahi S., Hainque B., et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 28 (2004) 993-997
125. Yu R., Kim C.S., and Kang J.H. Inflammatory components of adipose tissue as target for treatment of metabolic syndrome. Forum Nutr 61 (2009) 95-103
126. Hersoug L.G., and Linneberg A. The link between the epidemics of obesity and allergic diseases: does obesity induce decreased immune tolerance?. Allergy 62 (2007) 1205-1213
127. Pertwee R.G. Pharmacological actions of cannabinoids. Handb Exp Pharmacol (2005) 1-51
128. Molina-Holgado F., Pinteaux E., Moore J., Molina-Holgado E., Gibson R.M., Guaza C., and Rothwell N.J. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurones and glia. J Neurosci 23 (2003) 6470-6474
129. Rubio-Araiz A., Arevalo-Martin A., Gomez-Torres A., Navarro-Galve B., Garcia-Ovejero D., Suetterlin P., Sanchez-Heras E., Molina-Holgado E., and Molina-Holgado F. The endocannabinoid system modulates a TNF immediate transient pathway that induces neural stem cell proliferation. Mol Cell Neurosci 38 3 (2008 Jul) 374-380